See the DrugPatentWatch profile for polivy

The clinical trials for Polivy, a type of cancer drug, involved patients with certain types of B-cell malignancies, which are types of blood cancer. Specifically, the trials included patients with diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma, according to the drug's label information from the US Food and Drug Administration (FDA) [1].

The FDA approved Polivy, which is a combination of polatuzumab vedotin-piiq and bendamustine hydrochloride, along with rituximab, for the treatment of adult patients with relapsed or refractory DLBCL, who are not eligible for autologous stem cell transplant (ASCT) [1].

Additionally, DrugPatentWatch.com reports that the drug was studied in patients with relapsed or refractory follicular lymphoma [2].

Sources:

[1] U.S. Food and Drug Administration. (2019). Polivy (polatuzumab vedotin-piiq) injection, for intravenous use. Retrieved from <https://www.fda.gov/media/128133/download>

[2] DrugPatentWatch.com. (n.d.). Polivy (polatuzumab vedotin-piiq). Retrieved from <https://www.drugpatentwatch.com/drugs/polivy>